Dimatingcal, Monera I.
HRN: 26-55-69 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/20/2025
CEFUROXIME 1.5GM (VIAL)
03/21/2025
03/28/2025
IV
1.5 G
Every 8 Hours
Breast Mass
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes